Health

SHERIDAN, WYOMING – July 29, 2025 – As the Alzheimer’s treatment landscape evolves beyond legacy amyloid-targeting approaches, five upcoming trial readouts are expected to deliver pivotal data that could shift both clinical practice and market leadership. From repurposed GLP-1 drugs to precision antibody therapies, leading pharma and biotech players are advancing differentiated strategies to address persistent unmet needs in Alzheimer’s care.

Data Milestones Poised to Shape the Post-Amyloid Era

SHERIDAN, WYOMING – July 29, 2025 – As Q2 earnings season ramps up, a diverse group of biotech leaders—ranging from Sarepta Therapeutics to Vertex Pharmaceuticals—find themselves navigating vastly different strategic terrain. From regulatory setbacks and gene therapy scrutiny to CRISPR approvals and pain therapy innovation, this quarter’s results could redefine investor confidence and reshape R&D roadmaps across the sector.

Sarepta Confronts Regulatory Turbulence and Gene Therapy Fallout

SHERIDAN, WYOMING – July 25, 2025 – Philips has secured FDA 510(k) clearance for its next-generation UroNav platform, reinforcing the company’s leadership in image-guided interventions for prostate cancer. The upgraded UroNav 2.0 system is designed to unify MR/ultrasound fusion imaging with advanced workflow integration, helping clinicians deliver more accurate, less invasive, and highly personalized focal therapies.

SHERIDAN, WYOMING – July 25, 2025 – Philips and Radboud university medical center (Radboudumc) are conducting one of the first large-scale studies to explore the impact of prolonged physical activity on atrial fibrillation, leveraging wearable monitoring technology during the 4Days Marches in the Netherlands. The collaboration combines clinical expertise with cutting-edge sensor technology to better understand how exercise influences this widespread heart rhythm disorder.

Continuous Monitoring for Deeper Insight into Atrial Fibrillation

SHERIDAN, WYOMING – July 25, 2025 – Philips Foundation has announced the results of its 2024 activities in a newly published Annual Report, celebrating a milestone year that brought quality healthcare access to 46.5 million people globally—up from 28 million in 2023. The results mark a significant stride toward the Foundation’s 2030 goal of reaching 100 million underserved individuals each year.

Strategic Projects and Investments Drive Expansion

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) has confirmed the exchange ratio for its 2024 dividend, announcing a share-based conversion rate of one new common share for every 23.6353 existing shares. The ratio was determined based on the volume-weighted average price of Philips shares traded on Euronext Amsterdam across May 30, June 2, and June 3, 2025, which stood at EUR 20.0600.

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips has initiated a major international clinical trial to evaluate its new ultra-low X-ray dose technology designed for coronary procedures. The RADIQAL trial aims to generate real-world evidence that the innovation can significantly reduce radiation exposure for both patients and clinical staff without compromising the image quality or procedural performance critical to interventional cardiology.

Strategic push for radiation dose reduction in cardiology

SHERIDAN, WYOMING – July 25, 2025 – In a significant move reshaping national vaccine policy, the U.S. Department of Health and Human Services (HHS) has announced it will eliminate thimerosal from all influenza vaccines distributed in the United States. The decision follows a unanimous vote by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) on June 26, 2025, and marks the end of an era for a preservative that has been both a practical necessity and a source of public debate for over two decades.

SHERIDAN, WYOMING – July 25, 2025 – Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx). The application sought approval for this regimen as a second-line treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.

SHERIDAN, WYOMING – July 25, 2025 – Genentech has confirmed another round of workforce reductions at its South San Francisco headquarters, cutting 87 jobs effective September 15, 2025. The move comes as part of a broader, ongoing strategy to recalibrate operations and align resources with evolving scientific and business priorities.